Context: Although neuronal cell adhesion molecule (NrCAM) has been reported to be overexpressed in papillary thyroid cancer (PTCs), its role in this disease remains largely unclear.
Experimental Design: Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to evaluate messenger RNA expression of investigated genes. The functions of knockdown and ectopic expression of NrCAM in thyroid cancer cells were determine by a series of in vitro and in vivo experiments.
Results: We found that NrCAM was highly expressed in PTCs and demonstrated that NrCAM might be a potential marker for preoperative diagnosis of PTC. Moreover, NrCAM depletion dramatically inhibited thyroid cancer cell growth, invasiveness and tumorigenic potential in nude mice. On the other hand, ectopic expression of NrCAM significantly enhanced its tumor-promoting effects. Mechanically, NrCAM exerted its oncogenic function by activating MAPK/Erk and PI3K/Akt pathways via its ectodomain shedding and binding to EGFR and a4b1 integrins. In turn, these 2 pathways were also responsible for NrCAM overexpression through GSK3b/b-catenin signaling axis in thyroid cancer cells. Similar results were also found in transgenic mice with thyroid-specific knockin of oncogenic Braf V600E (TPO-Cre/LSL-Braf
V600E
).
Conclusions: Our data first reveal positive feedback loops between NrCAM and major signaling pathways contributing to thyroid tumorigenesis by modulating tumor microenvironment, and suggest that NrCAM may represent a potential diagnostic marker and therapeutic target for thyroid cancer. (J Clin Endocrinol Metab 102: 613-624, 2017) E pithelial follicular cell-derived thyroid cancer is the most frequently occurring endocrine malignancy and its incidence has increased threefold over the past 30 years (1, 2) . The most common type is papillary thyroid cancer (PTC), which accounts for .80% of all thyroid cancers.
PTCs are usually not aggressive and curable with 5-year survival of over 95%; however, occasionally, they dedifferentiate into more aggressive and lethal thyroid cancers (3). Genetic alterations of major signaling pathways including MAPK/Erk and PI3K/Akt pathways are the driving force behind thyroid tumorigenesis and progression (4) . Previous genetic studies report over 70% of activating somatic alterations of gene encoding effectors in MAPK/ Erk pathway, including point mutations of BRAF and the RAS genes particularly the former (5) . Genetic alterations in members of PI3K/Akt pathway, such as PTEN, PIK3CA and AKT1, have also been frequently found in thyroid cancers (4, 6, 7) .
In addition to genetic alterations, other mechanisms such as changes in cell adhesion have been implicated in all steps of tumor progression such as tumor growth and metastasis, and affect the biological characteristics and behavior of the cancer (8) . Cell-adhesion molecules belonging to the immunoglobulin (Ig) superfamily (Ig-SF) play a central role in cell-cell adhesion, and there is growing body of evidence suggesting the association of a number of these molecules with tumor progression and a metastatic phenotype (9) . Neuronal cell adhesion molecule (NrCAM), a member of Ig-SF, is a 200-to 220-kDa transmembrane protein composed of 5 fibronectin (FN) type III repeats, 6 Ig-like C2-type domains in the extracellular region, and a highly conserved cytoplasmic tail (10, 11) . NrCAM was initially discovered and was widely studied in central and peripheral nervous system (10) . Recently, it was found to be aberrantly expressed in human cancers (12) (13) (14) (15) , and increased expression of NrCAM enhanced cell proliferation and motility, and conferred cell transformation in melanoma and colon cancer cells by constitutively activating the extracellular signal-regulated kinase and Akt pathways via interaction with a4b1 integrins (16, 17) . A previous study showed that NrCAM was upregulated at messenger RNA (mRNA) and protein levels regardless of tumor stage (18) , suggesting that it may be early molecular event in PTC development. However, its exact biological roles in thyroid tumorigenesis are not fully understood.
In this study, we found high-level expression of NrCAM in PTCs compared with control subjects and demonstrated that NrCAM had the potential to be a powerful marker for PTC diagnosis. Importantly, we first revealed positive feedback loops between NrCAM and major signaling pathways contributing to thyroid tumorigenesis in cell and transgenic mouse models.
Materials and Methods
The details are described in supplemental data.
Results

Increased expression of NrCAM is a potential diagnostic marker for PTCs
We examined mRNA expression of NrCAM in 16 primary PTCs and their matched nontumor tissues (control subjects) by quantitative real-time PCR (qRT-PCR) assay. As shown in Figure 1 (A), NrCAM expression was significantly upregulated in PTCs compared with control subjects (P , 0.001). This was further supported by The Cancer Genome Atlas RNA-Seq dataset that NrCAM expression in PTCs was significantly higher than that in normal controls or matched normal thyroid tissues regardless of pathological subtypes of PTC [ Fig. 1(B) and 1(C) ].
To determine whether NrCAM can be used as a marker for preoperative diagnosis of PTC, we investigated NrCAM expression in a cohort of fine-needle aspiration biopsy (FNAB) specimens from 88 patients with thyroid nodules, including 43 conventional PTCs (CPTCs) and 45 benign nodules. Similarly, NrCAM expression was significantly higher in CPTCs than that in benign nodules (P , 0.001) [ Fig. 1(D) ]. Next, we set the cut-off value (10.89) according to the Youden index and evaluated the diagnostic accuracy of NrCAM by employing receiver operating characteristic curve. As shown in Figure 1 (E), the receiver operating characteristic curve showed a high area under the curve for NrCAM, suggesting that increased expression of NrCAM may be a potential diagnostic marker for PTCs. Further analysis showed that the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of NrCAM on FNABs was 95.45%, 82.22%, 84.00%, 94.87% and 77.68%, respectively [ Fig. 1(F) ]. Given that the BRAF V600E mutation is considered to be a powerful marker for PTCs because it represents a stable marker with 100% specificity and high sensitivity for PTC diagnosis (19) , we tested the BRAF V600E mutation and explored its diagnostic value for PTCs in this study. This mutation was detected in 34 of 44 (77.27%) PTCs, and was not found in benign nodules. Its sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy were 77.27%, 100%, 100%, 81.82%, and 77.27%, respectively [ Fig. 1(F) ]. Altogether, these data demonstrated that NrCAM and the BRAF V600E mutation had a similar diagnostic accuracy for PTCs, supporting the potential value of NrCAM in PTC diagnosis.
NrCAM promotes thyroid cancer cell growth in vitro and in vivo
To illustrate the potential function of NrCAM, a series of in vitro biological experiments were performed with loss-of-function and gain-of-function of NrCAM. NrCAM mRNA expression in thyroid cancer cells was determined by conventional RT-PCR assay (Supplemental Fig. 1 ). As shown in Figure 2 press.endocrine.org/journal/jcem We also tested the effects of NrCAM depletion on cell cycle distributions and apoptosis in thyroid cancer cells. As shown in Figure 
NrCAM enhances thyroid cancer cell migration and invasion
Given the involvement of NrCAM in cell motility (16, 17) , we thus attempted to investigate the effect of NrCAM on the migration and invasion abilities of thyroid cancer cells. As shown in Supplemental Figure 4 (A), there were a significantly lower number of migrated cells in the siNrCAM-3 transfected cells than in the si-NC transfected cells. Moreover, the invasion assay showed that NrCAM knockdown significantly decreased the ability of cells to pass through the Matrigel-coated membrane. On the other hand, ectopic expression of NrCAM in IHH4 cells dramatically enhanced cell migration and invasion [Supplemental Fig. 4(B) ]. These data suggest that there is a strong link between increased expression of NrCAM and metastatic phenotypes in thyroid cancer cells.
Ectodomain of NrCAM interacts with a4b1 integrins and EGFR to modulate major signaling pathways in thyroid cancer cells
To clarify molecular mechanism underlying tumorpromoting effects of NrCAM in thyroid cancer, we first tested the effect of NrCAM depletion on the activities of the MAPK/Erk and PI3K/Akt pathways, which play a fundamental role in the regulation of cell transformation and survival in thyroid tumorigenesis (4, 16) . As shown in Figure 3 (A), NrCAM knockdown significantly inhibited the activities of both pathways in thyroid cancer cells, characterized by reduced phosphorylation of Akt and Erk. Next, we attempted to unravel the mechanism for the activation of these 2 pathways by NrCAM. L1CAM, a close homolog of NrCAM, is identified to mediate cell signals by interacting with cell surface receptors (20, 21) . Thus, we used a reciprocal coimmunoprecipitation assay to determine the interaction of NrCAM with several surface receptors such as integrins and EGFR. As expected, our data demonstrated that NrCAM interacted with a4b1 integrins to form a complex [ Fig. 3(B) ]. This was supported by a previous study that NrCAM ectodomain was shed from cell surface, and formed a complex with integrins to activate the extracellular signal-regulated kinase in melanoma and NIH3T3 cells (18) . In addition, we first revealed an interaction of NrCAM with EGFR on the cell surface in this study [ Fig. 3(B) ]. Immunofluorescence assay demonstrated colocalization of NrCAM and integrin a4 or EGFR on the cell membrane of FTC133 and C643 cells [Supplemental Fig. (5) ], further supporting their extracellular binding. NrCAM depletion significantly inhibited the activation of a4b1 integrins and EGFR compared with control, characterized by reduced phosphorylation of FAK and EGFR [ Fig. 3(C) ].
To further determine that NrCAM ectodomain is shed from cell surface to promote cell transformation by altering cellular microenvironment, we first determined the release of NrCAM ectodomain in the conditioned medium of K1 and IHH4 cells by western blotting. The results showed that ectodomain shedding of NrCAM in K1 cells was stronger than IHH4 cells [ Fig. 3(D) , upper Blockage of NrCAM ectodomain and inhibition of integrins and EGFR attenuate the oncogenic effects of NrCAM in thyroid cancer cells It is clear that L1CAM binds to integrins via both arginine-glycine-aspartate (RGD)-dependent way by its sixth Ig-like repeat and RGD-independent ways by its third FN-like repeat (22) . NrCAM lacks the RGD domain, but its third FN-like domain has a 42% identity amino acid sequence with L1CAM, we thus speculated that NrCAM had the potential to interact with integrins by its third FN-like domain. To test this, FTC133 cells expressing both NrCAM and a4b1 integrins were incubated with NrCAM monoclonal antibody directed to this region, and the ability of migration and invasion was assessed by Transwell assays. As shown in Figure 4 press.endocrine.org/journal/jcemFTC133 cells compared with IgG antibody [ Fig. 4(B) ]. However, NrCAM antibody did not influence the release of NrCAM ectodomain and expression of endogenic NrCAM in FTC133 cells (Supplemental Fig. 6 ). Taken together, these data suggest that high-affinity specific antibodies to NrCAM may be an effective strategy for the treatment of NrCAM-positive human cancers.
To further determine oncogenic effects of NrCAM in thyroid cancer cells through activating integrins and EGFR signaling, gene-specific siRNA was used to downregulate ITGB1 (coding for integrin b1) expression in pCMVNrCAM transfected IHH4 cells [ Fig. 4(C) ]. As expected, our data showed that proliferation-and invasivenesspromoting effects of NrCAM were dramatically attenuated upon ITGB1 depletion [ Fig. 4(D) and 4(E) ]. In addition, we used gefitinib to inhibit EGFR activation in the same cells [ Fig. 4(F) ], and similarly found that gefitinib significantly inhibited proliferation-promoting effect of NrCAM [ Fig. 4(G) ].
Positive feedback loops Between NrCAM and major signaling pathways in thyroid cancer cells
Cell-adhesion molecules modulate signal-transduction pathways by interacting with cell surface receptors. Conversely, signaling pathways can also modulate these cell-adhesion molecules, altering the interactions between cells and their environment (23) . Thus, we speculated that the expression and function of NrCAM might be regulated by major pathways such as the MAPK/Erk and PI3K/Akt pathways in thyroid cancer cells. First, we investigated the relationship between NrCAM expression and the BRAF V600E mutation in a cohort of PTCs. The results showed that NrCAM expression was significantly higher in the BRAF V600E -positive cases than in the BRAF V600E -negative cases regardless of pathological subtypes of PTC, as supported by the information from TGCA database [ Fig.  5(A) ]. Next, we incubated BCPAP (harboring the BRAF V600E mutation) and FTC133 (PTEN null) cells in 10% FBS for 24 hours followed by serum-free medium culture, and treated with 1 mm PLX4032 for 10 hours or 10 mm MK2206 for 24 hours, respectively. As shown in Figure 5 (B), PLX4032 and MK2206 dramatically inhibited Erk phosphorylation in BCPAP cells and Akt phosphorylation in FTC133 cells, respectively. Importantly, we found that NrCAM expression was remarkably downregulated upon inhibition of the MAPK/Erk and PI3K/Akt cascades in both conditioned medium and lysates from these cells (Supplemental Fig. 7) . Given that NrCAM has been indicated as a target of the b-catenin-TCF/LEF signaling in melanoma and colon cancer (16), we thus assumed that the MAPK/Erk and PI3K/Akt pathways regulated NrCAM expression through b-catenin-TCF/LEF signaling. Indeed, inhibition of these 2 pathways by PLX4032 or MK2206 significantly attenuated b-catenin expression [ Fig. 5(B) ]. It is well known that b-catenin is phosphorylated in its N-terminal domain by GSK-3b, which is responsible for its degradation by the ubiquitin/proteasome pathway (24) (25) (26) (27) . Moreover, the MAPK/Erk and PI3K/Akt signaling pathways have been demonstrated to phosphorylate GSK-3b, which leads to its inactivation and augmentation of b-catenin-TCF/LEF transcriptional activity (28) (29) (30) . This was supported by our data that GSK-3b phosphorylation was inhibited upon inactivation of the MAPK/Erk and PI3K/Akt cascades [ Fig. 5(B) ]. Next, we further assessed the effect of inhibition of these 2 pathways on nucleus translocation of b-catenin by using immunofluorescence. As expected, expression and nuclear accumulation of b-catenin was dramatically inhibited when the cells were treated with PLX4032 or MK2206 compared with controls [ Fig. 5(C) ]. Given that NrCAM ectodomain shedding in fibroblasts and melanoma cells is regulated by metalloproteases (MMPs) (18), we next tested the effect of the MAPK/Erk and PI3K/Akt cascades on the expression of a panel of MMP genes. As shown in Supplemental Figure 8 , inhibition of MAPK pathway by PLX4032 in BCPAP cells or PI3K/Akt pathway by MK2206 in FTC133 cells caused a significant decrease in the expression of these genes except for MMP14 gene in FTC133 cells. Collectively, these data support that constitutive activation of the MAPK/Erk and PI3K/Akt cascades not only upregulates NrCAM expression by GSK-3b/b-catenin-TCF/LEF signaling, also promotes NrCAM ectodomain shedding by modulating the expression of several members of MMP family in thyroid cancer cells.
To further confirm the above conclusions, TPO-Cre/ LSL-Braf V600E mice were treated with a combination of PLX4720 and GSK12020122 or vehicle. Compared with vehicle treatment, combination treatment of 2 inhibitors significantly increased the weight of mice [Supplemental Fig. 9(A) ] and caused a significant reduction of tumor volume and weight [Supplemental Fig. 9(B) ]. Immunohistochemical staining in thyroid tumors of these mice showed that Erk phosphorylation was remarkably inhibited in mice treated with a combination of PLX4720 and GSK12020122 compared with control mice, which consequently caused a decreased expression of GSK3b phosphorylation, b-catenin and NrCAM [ Fig. 5(D) and 5(E)]. These in vivo data further support the positive feedback loops between NrCAM and major signaling pathways in thyroid cancer. Briefly, the activation of MAPK/Erk and PI3K/Akt pathways by some somatic genetic alterations such as BRAF V600E mutation and PTEN inactivation can upregulate NrCAM expression by GSK-3b/b-catenin-TCF/LEF signaling axis, and promote MMPs-mediated shedding of NrCAM into cellular microenvironment, in turn, NrCAM enhances the output of these pathways through binding to integrins and EGFR on the surface of the same cells via an autocrine action. In addition, NrCAM can also bind to these surface receptors on the surface of neighboring cells no/low expressing NrCAM and activates their downstream signaling pathways contributing to cell growth, invasiveness and survival through a paracrine mechanism (Fig. 6 ).
Discussion
In this study, we provided strong evidences supporting the oncogenic effects of NrCAM in thyroid cancer. First, NrCAM was highly expressed in primary PTCs compared with matched nontumor tissues. Second, increased press.endocrine.org/journal/jcemexpression of NrCAM may be used as a potential diagnostic marker for PTCs. Third, NrCAM formed positive feedback loops with major signaling pathways such as the MAPK and PI3K/Akt pathways, contributing to thyroid tumorigenesis. Thyroid nodules are among the most common endocrine complains worldwide, which sometimes represents a significant diagnostic challenge in differentiating malignant from benign lesions. Although FNAB is the most reliable nonsurgical test and is widely used in diagnosing thyroid nodules, about 20% of FNABs are diagnosed as indeterminate cytological findings that cannot distinguish malignant from benign nodules (31, 32) . Thus, there is compelling need for additional methods to improve diagnostic accuracy of thyroid nodules. In this study, we demonstrated that NrCAM expression was significantly upregulated in both tumor tissues and FNABs from PTC patients compared with control subjects, which was further confirmed by the information from The Cancer Genome Atlas database. We also preliminarily defined the specificity, sensitivity and accuracy of NrCAM in assessing malignant thyroid nodules. Compared with the BRAF V600E mutation, a widely used specific biomarker for PTC diagnosis (19) , NrCAM exhibited a similar diagnostic accuracy with both high specificity and sensitivity, suggesting that NrCAM has the potential to be a diagnostic biomarker for PTCs.
Although NrCAM has been reported to be upregulated in PTCs (18) , its roles in thyroid tumorigenesis remain totally unclear. We thus tested its biological functions in thyroid cancer by a series of in vitro and in vivo experiments. Our data showed that NrCAM depletion in thyroid Figure 6 . Schematic model of positive feedback loops between NrCAM and major signaling pathways in thyroid tumorigenesis. Aberrant activation of MAPK/Erk and PI3K/Akt signaling pathways by some somatic genetic alterations such as BRAF V600E mutation and PTEN inactivation enhances the phosphorylation of GSK3b, resulting in the inability of GSK3b to phosphorylate b-catenin. As a result, b-catenin is accumulated in the cytoplasm, subsequently translocates into the nucleus where it binds to TCF/LEF and acts as its coactivator to stimulate the transcription of NrCAM. In turn, NrCAM ectodomain is shed from cell surface by MMPs, and further elevates the output of MAPK/Erk and PI3K/Akt signaling pathways by binding to a4b1 integrins and EGFR on the surface of the same cells via an autocrine manner. In addition, NrCAM also interacts with these surface receptors on the surface of neighboring cells no/low expressing NrCAM and activates their downstream signaling pathways by a paracrine mechanism, promoting cell proliferation, migration, invasion, and survival.
cancer cells showed significant growth-inhibitory effect by inhibition of cell proliferation and colony formation in vitro and tumorigenic potential in nude mice in vivo. Moreover, NrCAM knockdown induced cell cycle arrest and apoptosis, and inhibited cell migration and invasion in thyroid cancer cells. On the other hand, ectopic expression of NrCAM significantly enhanced cell growth and invasiveness, further supporting that it is a functional oncogene in thyroid cancer.
Accumulating evidences indicate that the functional interaction of many cell adhesion molecules with receptor tyrosine kinases and other signal transducers is widespread phenomenon that may have implications for various physiological and pathological processes including tumorigenesis (23) . Thus, to better understand oncogenic effects of NrCAM and its possible involvement in thyroid tumorigenesis, we investigated the effect of NrCAM on the activities of major signaling pathways in thyroid cancer cells. Our data showed that NrCAM activated the MAPK/Erk and PI3K/Akt cascades through interacting with a4b1 integrins and EGFR. This was partially supported by a previous study that extracellular domain of NrCAM was shed into culture medium by MMPs, and interacted with integrins on the cell surface to confer cell growth by activating various signaling pathways in melanoma and NIH3T3 cells (17) . Notably, in this study, we first demonstrated that NrCAM ectodomain formed a complex with EGFR to activate its downstream signaling cascades, contributing to cell transformation. EGFR (also known as ERBB1) is a transmembrane receptor tyrosine kinase that is widely overexpressed in a variety of human cancers including thyroid cancer (33, 34) , and constitutively activated EGFR promotes cell proliferation and inhibits apoptotic mechanisms by the MAPK/Erk and PI3K/Akt pathways (35) . Thus, inhibition of NrCAM-EGFR signaling may be a potential therapeutic strategy for thyroid cancer. It is noteworthy that blockage of NrCAM ectodomain with its monoclonal antibody causes a marked reduction in cell migration and invasion by inhibiting NrCAM-integrin signaling, suggesting that the use of high-affinity NrCAM antibody may help to improve the therapy of NrCAMpositive cancers. Moreover, integrin b1 depletion by siRNA and EGFR inhibitor gefitinib effectively attenuated the growth-and invasiveness-promoting effects of NrCAM, further supporting that NrCAM plays an oncogenic role in thyroid cancer cells by activating integrin and EGFR signaling.
It is the fact that some cell adhesion molecules regulate and, conversely, are regulated by some signaling pathways during tumorigenesis (23) . This was supported by our data that inhibition of the MAPK/Erk and PI3K/Akt cascades in thyroid cancer cells significantly decreased NrCAM expression. Further studies revealed that these 2 pathways modulated NrCAM expression by GSK-3b/ b-catenin-TCF/LEF signaling axis in thyroid cancer cells. This was consistent with our in vivo studies that inhibition of MAPK/Erk signaling cascade by RAF and MEK inhibitors in thyroid cancer of TPO-Cre/LSL-Braf V600E mice caused a significant decreased expression of GSK3b phosphorylation, b-catenin and NrCAM. Collectively, our data suggest positive feedback loops between NrCAM and major signaling pathways in thyroid cancer cells, which promote cell proliferation, invasiveness and survival through both autocrine and paracrine mechanisms.
In summary, we found highly increased expression of NrCAM in primary PTCs and determined its potential diagnostic value in PTCs. Moreover, our data supported an oncogenic role of NrCAM in thyroid tumorigenesis, and revealed positive feedback loops between NrCAM with major signaling pathways, which had a crucial role in tumor progression. The findings described here show that functional implications of the crosstalk between cell adhesion molecules such as NrCAM and signaling pathways in the initiation and progression of malignancies will certainly be a key focus of future cancer studies including thyroid cancer.
